TY - JOUR
T1 - Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload
AU - Cappellini, Maria D.
AU - Taher, A.
PY - 2008/9
Y1 - 2008/9
N2 - Background: Chronic iron overload from frequent blood transfusions to treat patients with severe anaemias leads to significant morbidity and mortality. While deferoxamine, the current standard of care, is an effective iron chelator, it requires subcutaneous infusion for 8-12 h/ day, 5-7 days/week. This regimen is problematic and impacts significantly on patients' daily life. Objective: To evaluate the efficacy and tolerability of deferasirox, a once-daily oral iron chelator. Method: To review the available data reported in peer-reviewed journals (using PubMed) and at medical conferences. Results/conclusions: Deferasirox is effective in reducing or maintaining iron burden in patients with transfusion-dependent anaemias. As deferasirox is orally administered, the inconvenience of parenteral administration with deferasirox is avoided. Deferasirox improves patient satisfaction and is expected to improve compliance with iron chelation therapy.
AB - Background: Chronic iron overload from frequent blood transfusions to treat patients with severe anaemias leads to significant morbidity and mortality. While deferoxamine, the current standard of care, is an effective iron chelator, it requires subcutaneous infusion for 8-12 h/ day, 5-7 days/week. This regimen is problematic and impacts significantly on patients' daily life. Objective: To evaluate the efficacy and tolerability of deferasirox, a once-daily oral iron chelator. Method: To review the available data reported in peer-reviewed journals (using PubMed) and at medical conferences. Results/conclusions: Deferasirox is effective in reducing or maintaining iron burden in patients with transfusion-dependent anaemias. As deferasirox is orally administered, the inconvenience of parenteral administration with deferasirox is avoided. Deferasirox improves patient satisfaction and is expected to improve compliance with iron chelation therapy.
KW - Deferasirox
KW - Effective
KW - Exjade
KW - Transfusional iron overload
UR - http://www.scopus.com/inward/record.url?scp=52249085605&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=52249085605&partnerID=8YFLogxK
U2 - 10.1517/14656566.9.13.2391
DO - 10.1517/14656566.9.13.2391
M3 - Article
C2 - 18710363
AN - SCOPUS:52249085605
VL - 9
SP - 2391
EP - 2402
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
SN - 1465-6566
IS - 13
ER -